Ontology highlight
ABSTRACT:
SUBMITTER: Moore NF
PROVIDER: S-EPMC4226718 | biostudies-literature | 2014 Sep
REPOSITORIES: biostudies-literature
Moore Nathan F NF Azarova Anna M AM Bhatnagar Namrata N Ross Kenneth N KN Drake Lauren E LE Frumm Stacey S Liu Qinsong S QS Christie Amanda L AL Sanda Takaomi T Chesler Louis L Kung Andrew L AL Gray Nathanael S NS Stegmaier Kimberly K George Rani E RE
Oncotarget 20140901 18
Mutations in the ALK tyrosine kinase receptor gene represent important therapeutic targets in neuroblastoma, yet their clinical translation has been challenging. The ALK(F1174L) mutation is sensitive to the ALK inhibitor crizotinib only at high doses and mediates acquired resistance to crizotinib in ALK-translocated cancers. We have shown that the combination of crizotinib and an inhibitor of downstream signaling induces a favorable response in transgenic mice bearing ALK(F1174L)/MYCN-positive n ...[more]